ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN
But 'Unique Side Effects' A Concern
Executive Summary
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
You may also be interested in...
Pfizer Testing Warranty Offer With Xalkori, May Expand It To ‘Multiple’ Products
Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.
Pfizer Triples Down On CDK Inhibition In Breast, Other Cancers
Pfizer is looking to address breast cancer resistant to Ibrance and other CDK4/6 inhibitors, but sees potential paths to earlier lines of treatment and additional tumors.
Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.